Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
EVOK 
Evoke Pharma Inc (EVOK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: EVOK (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -49.88% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.17M USD | Price to earnings Ratio - | 1Y Target Price 18 |
Price to earnings Ratio - | 1Y Target Price 18 | ||
Volume (30-day avg) 22795 | Beta 0.12 | 52 Weeks Range 2.50 - 8.10 | Updated Date 03/30/2025 |
52 Weeks Range 2.50 - 8.10 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.81 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-03-12 | When Before Market | Estimate -0.63 | Actual -0.77 |
Profitability
Profit Margin -52.22% | Operating Margin (TTM) -36.08% |
Management Effectiveness
Return on Assets (TTM) -26.46% | Return on Equity (TTM) -240.09% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -4271036 | Price to Sales(TTM) 0.41 |
Enterprise Value -4271036 | Price to Sales(TTM) 0.41 | ||
Enterprise Value to Revenue 0.05 | Enterprise Value to EBITDA -0.36 | Shares Outstanding 1492860 | Shares Floating 1231801 |
Shares Outstanding 1492860 | Shares Floating 1231801 | ||
Percent Insiders 5.02 | Percent Institutions 14.64 |
Analyst Ratings
Rating 4 | Target Price 18 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Evoke Pharma Inc
Company Overview
History and Background
Evoke Pharma, Inc. is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal (GI) disorders and diseases. Founded in 2007, the company went public in 2010. Its primary focus has been on Gimoti, a nasal spray formulation of metoclopramide for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Core Business Areas
- Pharmaceutical Development and Commercialization: Evoke Pharma focuses on developing and commercializing pharmaceutical products, primarily in the gastrointestinal area, with a focus on nasal spray drug delivery.
Leadership and Structure
Matt D'Onofrio is the current CEO of Evoke Pharma. The company has a board of directors that oversees the company's operations and strategy.
Top Products and Market Share
Key Offerings
- Gimoti: Gimoti is a nasal spray formulation of metoclopramide used to treat symptoms of acute and recurrent diabetic gastroparesis in adults. Market share data is limited due to the specific niche it serves and the competitive landscape. The competitors include oral metoclopramide and other medications used off-label for gastroparesis. The main competitors in the gastroparesis medication market are Teva Pharmaceutical (TEVA), and Salix Pharmaceuticals (acquired by Valeant Pharmaceuticals, now Bausch Health Companies (BHC)).
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high research and development costs, stringent regulatory requirements, and intense competition. The GI therapeutics market is driven by the prevalence of GI disorders and the demand for effective treatments.
Positioning
Evoke Pharma is a smaller player focusing on a specific unmet need within the GI marketu2014diabetic gastroparesis. Its competitive advantage lies in its nasal spray delivery method, which can bypass the digestive system and provide faster relief.
Total Addressable Market (TAM)
The gastroparesis market is estimated to be worth hundreds of millions of dollars annually, globally. Evoke Pharma, with Gimoti, is aiming to capture a significant portion of this market by offering a novel delivery method.
Upturn SWOT Analysis
Strengths
- Novel nasal spray delivery for metoclopramide
- Addresses an unmet need in diabetic gastroparesis
- Patent protection for Gimoti
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Reliance on a single product (Gimoti)
- Commercialization challenges for a small company
Opportunities
- Expansion of Gimoti's indications
- Partnerships with larger pharmaceutical companies
- Development of new GI therapeutics
Threats
- Competition from generic metoclopramide and other treatments
- Regulatory hurdles and delays
- Adverse events or safety concerns related to Gimoti
Competitors and Market Share
Key Competitors
- TEVA
- BHC
Competitive Landscape
Evoke Pharma faces stiff competition from larger, established pharmaceutical companies. Its advantage lies in its novel delivery system, but its small size and limited resources pose challenges.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven primarily by the development and commercialization of Gimoti.
Future Projections: Future growth depends on the successful commercialization of Gimoti, potential label expansions, and new product development.
Recent Initiatives: Recent initiatives likely focus on increasing Gimoti sales, marketing efforts, and exploring potential partnerships.
Summary
Evoke Pharma is a small pharmaceutical company focused on GI disorders, with Gimoti as its key product. It addresses an unmet need in diabetic gastroparesis with a unique delivery method. However, it faces challenges due to limited resources and competition. Future success depends on effective commercialization and potential partnerships and label expansions and regulatory approvals.
Similar Companies
- TEVA
- BHC
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Market research reports
- Financial news sources
- Company Website
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Market data is subject to change. Accuracy is not guaranteed.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Evoke Pharma Inc
Exchange NASDAQ | Headquaters Solana Beach, CA, United States | ||
IPO Launch date 2013-09-25 | Co-Founder, CEO & Director Mr. Matthew J. D'Onofrio MBA | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 3 | Website https://www.evokepharma.com |
Full time employees 3 | Website https://www.evokepharma.com | ||
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.